Page last updated: 2024-11-01

ofloxacin and Fever of Unknown Origin

ofloxacin has been researched along with Fever of Unknown Origin in 7 studies

Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

Fever of Unknown Origin: Fever in which the etiology cannot be ascertained.

Research Excerpts

ExcerptRelevanceReference
"5 g piperacillin/tazobactam 3 times a day in patients with low-risk febrile neutropenia."9.11Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. ( Bethe, U; Breuer, K; Cornely, OA; Diehl, V; Fätkenheuer, G; Karthaus, M; Reichert, D; Salzberger, B; Schwonzen, M; Seifert, H; Ullmann, AJ; Wicke, T, 2004)
"We randomly assigned 760 consecutive adult patients with cancer in whom chemotherapy-induced neutropenia (<1000 neutrophils per cubic millimeter) was expected to occur for more than seven days to receive either oral levofloxacin (500 mg daily) or placebo from the start of chemotherapy until the resolution of neutropenia."9.11Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. ( Allione, B; Amadori, S; Bucaneve, G; Buelli, M; Cantaffa, R; Cilloni, D; D'Antonio, D; Del Favero, A; Deliliers, GL; Dionisi, MS; Fabbiano, F; Foà, R; Lauria, F; Martinelli, G; Martino, P; Menichetti, F; Micozzi, A; Nosari, AM; Specchia, G; Zuffa, E, 2005)
" One hundred forty-eight cases received levofloxacin and 137 received amikacin, both in combination with ceftazidime."5.38Empirical therapy with ceftazidime combined with levofloxacin or once-daily amikacin for febrile neutropenia in patients with neoplasia: a prospective comparative study. ( Bompolaki, I; Bozionelou, V; Falagas, ME; Kalpadaki, C; Karageorgopoulos, DE; Koutsounaki, E; Mitsikostas, P; Samonis, G; Sgouros, J; Taktikou, V, 2012)
"5 g piperacillin/tazobactam 3 times a day in patients with low-risk febrile neutropenia."5.11Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia. ( Bethe, U; Breuer, K; Cornely, OA; Diehl, V; Fätkenheuer, G; Karthaus, M; Reichert, D; Salzberger, B; Schwonzen, M; Seifert, H; Ullmann, AJ; Wicke, T, 2004)
"We randomly assigned 760 consecutive adult patients with cancer in whom chemotherapy-induced neutropenia (<1000 neutrophils per cubic millimeter) was expected to occur for more than seven days to receive either oral levofloxacin (500 mg daily) or placebo from the start of chemotherapy until the resolution of neutropenia."5.11Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. ( Allione, B; Amadori, S; Bucaneve, G; Buelli, M; Cantaffa, R; Cilloni, D; D'Antonio, D; Del Favero, A; Deliliers, GL; Dionisi, MS; Fabbiano, F; Foà, R; Lauria, F; Martinelli, G; Martino, P; Menichetti, F; Micozzi, A; Nosari, AM; Specchia, G; Zuffa, E, 2005)
" After an initial work-up for fever, patients were randomized to receive oral ofloxacin 400 mg immediately and twice daily thereafter in the hospital or as outpatients."5.08Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. ( Aziz, Z; Karim, M; Khan, MA; Khan, WA; Malik, IA, 1995)
" He had noticed high fever since one month ago, and had been treated with prednisolone with the diagnosis of fever of unknown origin in a hospital."3.69[A case report--typhoid fever complicated with liver and gallbladder abscess, treated for long-time as fever of unknown origin]. ( Fukuda, J; Irimajiri, S; Kawashima, I; Matsuoka, Y; Obana, M; Suzuki, A; Suzuki, H; Suzuki, T, 1997)
" One hundred forty-eight cases received levofloxacin and 137 received amikacin, both in combination with ceftazidime."1.38Empirical therapy with ceftazidime combined with levofloxacin or once-daily amikacin for febrile neutropenia in patients with neoplasia: a prospective comparative study. ( Bompolaki, I; Bozionelou, V; Falagas, ME; Kalpadaki, C; Karageorgopoulos, DE; Koutsounaki, E; Mitsikostas, P; Samonis, G; Sgouros, J; Taktikou, V, 2012)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (28.57)18.2507
2000's3 (42.86)29.6817
2010's2 (28.57)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Calleris, G1
Marra, G1
Corcione, S1
Oderda, M1
Cardellino, C1
Audagnotto, S1
Frea, B1
De Rosa, FG1
Gontero, P1
Samonis, G1
Koutsounaki, E1
Karageorgopoulos, DE1
Mitsikostas, P1
Kalpadaki, C1
Bozionelou, V1
Bompolaki, I1
Sgouros, J1
Taktikou, V1
Falagas, ME1
Cornely, OA1
Wicke, T1
Seifert, H1
Bethe, U1
Schwonzen, M1
Reichert, D1
Ullmann, AJ1
Karthaus, M1
Breuer, K1
Salzberger, B1
Diehl, V1
Fätkenheuer, G1
Bucaneve, G1
Micozzi, A1
Menichetti, F1
Martino, P1
Dionisi, MS1
Martinelli, G1
Allione, B1
D'Antonio, D1
Buelli, M1
Nosari, AM1
Cilloni, D1
Zuffa, E1
Cantaffa, R1
Specchia, G1
Amadori, S1
Fabbiano, F1
Deliliers, GL1
Lauria, F1
Foà, R1
Del Favero, A1
Baden, LR1
Malik, IA1
Khan, WA1
Karim, M1
Aziz, Z1
Khan, MA1
Kawashima, I1
Suzuki, T1
Suzuki, A1
Obana, M1
Suzuki, H1
Matsuoka, Y1
Irimajiri, S1
Fukuda, J1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Feasibility Study of the Use of Intermediate Doses of Cytarabine Associated With Autologous Hematopoietic Stem Cells as Consolidation Treatment of Young Adults With Low- or Intermediate-risk de Novo Acute Myeloid Leukemia[NCT03023384]547 participants (Anticipated)Observational [Patient Registry]2016-12-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

3 trials available for ofloxacin and Fever of Unknown Origin

ArticleYear
Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia.
    International journal of hematology, 2004, Volume: 79, Issue:1

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Bacterial Infections; Disease Susceptibili

2004
Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia.
    The New England journal of medicine, 2005, Sep-08, Volume: 353, Issue:10

    Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Agents; Bacte

2005
Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial.
    The American journal of medicine, 1995, Volume: 98, Issue:3

    Topics: Adult; Aged; Ambulatory Care; Feasibility Studies; Female; Fever; Fever of Unknown Origin; Humans; M

1995

Other Studies

4 other studies available for ofloxacin and Fever of Unknown Origin

ArticleYear
Miliary pulmonary infection after BCG intravesical instillation: a rare, misdiagnosed and mistreated complication.
    Le infezioni in medicina, 2017, Dec-01, Volume: 25, Issue:4

    Topics: Aged; Antitubercular Agents; BCG Vaccine; Bronchoalveolar Lavage Fluid; Carcinoma, Transitional Cell

2017
Empirical therapy with ceftazidime combined with levofloxacin or once-daily amikacin for febrile neutropenia in patients with neoplasia: a prospective comparative study.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2012, Volume: 31, Issue:7

    Topics: Aged; Amikacin; Anti-Bacterial Agents; Ceftazidime; Drug Therapy, Combination; Female; Fever of Unkn

2012
Prophylactic antimicrobial agents and the importance of fitness.
    The New England journal of medicine, 2005, Sep-08, Volume: 353, Issue:10

    Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Antineoplastic Agents; Bacterial Infections; Drug Res

2005
[A case report--typhoid fever complicated with liver and gallbladder abscess, treated for long-time as fever of unknown origin].
    Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases, 1997, Volume: 71, Issue:8

    Topics: Abscess; Adult; Anti-Infective Agents; Anti-Inflammatory Agents; Cholecystectomy; Diagnostic Errors;

1997